Volume 2 Supplement 1

Metabolism, Diet and Disease 2014: Cancer and metabolism

Open Access

The NADP+-dependent IDH1 mutation and its relevance for glioblastoma patient survival

  • Cornelis JF Van Noorden1
Cancer & Metabolism20142(Suppl 1):P79

https://doi.org/10.1186/2049-3002-2-S1-P79

Published: 28 May 2014

The metabolic consequences of the NADP+- dependent isocitrate dehydrogenase (IDH) 1 mutation was studied quantitatively in glioblastoma, the most aggressive form of brain tumor. The mutation is found in 70-80% of secondary glioblastoma. Metabolic rewiring of cells due to the mutation causes gliomagenesis by the production of 2-hydroxyglutarate. On the other hand, glioblastoma patients with the IDH1 mutation have a significant survival benefit of approx. one year. We found that the NADPH production capacity in glioblastoma is reduced by 38% when IDH1 is mutated [1]. We hypothesized that this reduced production capacity of NADPH, a major metabolite involved in detoxification processes, renders glioblastoma cells less resistant against irradiation and chemotherapy and thus prolong patient survival [2]. We also demonstrated that cellular metabolism is rewired in IDH1-mutated glioblastoma cells by elevated mitochondrial activity [3]. Further metabolic studies of human and rodent tissues showed that IDH activity is responsible for 65% of the NADPH production capacity in human brain and only for 15% in rodent brain whereas the pentose phosphate pathway was responsible for 85% of the NADPH production capacity in rodent tissues [4]. It explains why the pentose phosphate pathway was always linked with cancer and not IDH because most studies on metabolism and cancer have been performed in rodents. In conclusion, our metabolic study strongly suggests that the reduced NADPH production capacity in IDH1-mutated gliomablastoma makes cancer cells less resistant and as a consequence is at least partly responsible for prolonged patient survival.

Authors’ Affiliations

(1)
Department of Cell Biology and Histology, Academic Medical Center, University of Amsterdam

References

  1. Bleeker FE, et al: The prognostic IDH1( R132 ) mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathol. 2010, 119: 487-494. 10.1007/s00401-010-0645-6.PubMed CentralView ArticlePubMedGoogle Scholar
  2. Baldewpersad Tewarie NM, et al: NADP+ -dependent IDH1 R132 mutation and its relevance for glioma patient survival. Med Hypotheses. 2013, 80: 728-731. 10.1016/j.mehy.2013.02.022.View ArticlePubMedGoogle Scholar
  3. Navis AC, et al: Increased mitochondrial activity in a novel IDH1-R132H mutant human oligodendroglioma xenograft model: in situ detection of 2-HG and α-KG. Acta Neuropathol Commun. 2013, 1: 18-10.1186/2051-5960-1-18.PubMed CentralView ArticlePubMedGoogle Scholar
  4. Atai NA, et al: Differential activity of NADPH-producing dehydrogenases renders rodents unsuitable models to study IDH1R132 mutation effects in human glioblastoma. J Histochem Cytochem. 2011, 59: 489-503. 10.1369/0022155411400606.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Van Noorden; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement